GLP-1/GIP Dual Agonist Patent for Diabetes Treatment
Summary
USPTO granted patent US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. for long-acting GLP-1/GIP dual agonist compounds for treating Type II diabetes mellitus. The patent covers compounds with dual agonistic effects on glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors.
What changed
USPTO issued patent grant US12589158B2 to Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd. on March 31, 2026, covering long-acting GLP-1/GIP dual agonist compounds for Type II diabetes treatment. The patent (2 claims) protects compounds with dual agonistic activity on GLP-1 and GIP receptors, with CPC classifications A61K 47/64, A61P 3/04, A61P 3/10, and C07K 14/605. The original application (No. 18602255) was filed March 12, 2024.
Pharmaceutical companies developing similar dual-agonist diabetes therapies should conduct freedom-to-operate analyses before proceeding with clinical development or commercialization to assess potential patent infringement exposure. Competitors may need to explore licensing arrangements with the patent holder or design around the claimed compounds.
Archived snapshot
Mar 31, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
GLP-1/GIP dual agonist, preparation method and use thereof
Grant US12589158B2 Kind: B2 Mar 31, 2026
Assignee
Hangzhou Zhongmeihuadong Pharmaceutical Co., Ltd.
Inventors
Nan Zhang, Chunhua Jiang, Dongzhou Liu, Li Teng, Jiale Shen
Abstract
The present invention relates to long-acting GLP-1/GIP dual agonist compounds having a dual agonistic effect on glucagon-like peptide-1 (GLP-1) receptor and human glucose-dependent insulinotropic polypeptide (GIP) receptor. The present invention also relates to the use of said compounds in the manufacture of medicaments for treating Type II diabetes mellitus.
CPC Classifications
A61K 47/64 A61P 3/04 A61P 3/10 C07K 14/605
Filing Date
2024-03-12
Application No.
18602255
Claims
2
Related changes
Get daily alerts for USPTO Patent Grants - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Grants - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.